# Carcinoma of the Cervix

> **Malignant neoplasm** of the cervix, usually originating from **squamous epithelium (70–80%)** or **glandular epithelium (adenocarcinoma \~20%)** at the **transformation zone**.

## Risk Factors

1. **Persistent High-Risk HPV infection** (types 16, 18, 31, 33)
2. Early age of first sexual intercourse
3. Multiple sexual partners
4. Immunosuppression (e.g. HIV)
5. Smoking (nicotine → local immunosuppression)
6. Low socioeconomic status
7. Long-term use of combined oral contraceptives (>5 yrs)
8. High parity
9. Lack of cervical screening
10. Co-infections (e.g. chlamydia)

## FIGO 2018 Staging

### Stage I – Confined to cervix

- **IA1**: Stromal invasion \<3 mm
- **IA2**: Invasion 3–5 mm
- **IB1**: >5 mm depth, ≤2 cm width
- **IB2**: >2–≤4 cm
- **IB3**: >4 cm

### Stage II – Extends beyond cervix but not to pelvic wall or lower 1/3 vagina

- **IIA1**: ≤4 cm, no parametrial involvement
- **IIA2**: >4 cm, no parametrial involvement
- **IIB**: Parametrial involvement

### Stage III – Reaches pelvic wall, lower vagina, hydronephrosis, or lymph nodes

- **IIIA**: Lower 1/3 of vagina
- **IIIB**: Pelvic wall or hydronephrosis
- **IIIC1**: Pelvic lymph node metastasis
- **IIIC2**: Para-aortic lymph node metastasis

### Stage IV – Beyond pelvis or with bladder/rectum invasion

- **IVA**: Invades bladder or rectum mucosa
- **IVB**: Distant metastasis (lung, liver, bone)

## Clinical Features

### Symptoms

- **Early stage**: Often asymptomatic
- **Postcoital bleeding** (most common presenting feature)
- Intermenstrual bleeding
- Foul-smelling vaginal discharge
- Postmenopausal bleeding
- Dyspareunia
- Pelvic pain, low backache (advanced disease)

### Signs

- Cervix: friable, irregular, ulcerated, or fungating growth
- Contact bleeding on speculum exam
- Advanced:

  - Frozen pelvis
  - Hydronephrosis
  - Edema of legs (lymphatic obstruction)
  - Rectal or bladder involvement (fistulas)

## Investigations

### For Diagnosis

1. **Pap smear** (screening only)
2. **Colposcopy** with **directed punch biopsy**

   - Gold standard for diagnosis

3. **HPV testing** – for high-risk HPV subtypes

### For Staging

1. **Clinical examination under anesthesia** – bimanual and rectal exam
2. **Pelvic MRI** – best for local invasion
3. **CT scan / PET-CT** – lymph node and distant spread
4. **Cystoscopy / Proctoscopy** – bladder or rectum involvement
5. **IVU** – hydronephrosis (Stage IIIB)

## Management

- Multidisciplinary team (MDT) approach is essential
- **Radiotherapy ± chemotherapy** is mainstay in **advanced stages**

### Stage IA1

> Stromal invasion ≤3 mm, no LVSI

1. **Fertility desired**:

   - **Conization** with clear margins

2. **Completed family**:

   - **Total simple hysterectomy**

3. **LVSI present**:

   - Consider **radical trachelectomy** or **radical hysterectomy + lymphadenectomy**

### Stage IA2

> Invasion 3–5 mm

1. **Fertility preserving**:

   - **Radical trachelectomy** + pelvic lymphadenectomy

2. **No fertility desire**:

   - **Radical hysterectomy (Type II/III)** + **pelvic lymphadenectomy**

3. **Radiotherapy** alternative if unfit for surgery

### Stage IB1 and IB2 (≤4 cm)

- **Radical hysterectomy (Type III)** + pelvic ± para-aortic lymphadenectomy
- **OR** Radiotherapy + concurrent chemotherapy (if unsuitable for surgery)

### Stage IB3 and IIA2 (>4 cm)

- **Concurrent chemoradiotherapy** (CCRT)

  - External beam radiotherapy (EBRT) + weekly `cisplatin`
  - Followed by **intracavitary brachytherapy**

- Surgery not preferred due to high morbidity

### Stage IIB

> Parametrial involvement

- **Concurrent chemoradiotherapy**

  - `EBRT` + `cisplatin` + `brachytherapy`
  - No role for surgery

### Stage IIIA, IIIB, IIIC

- **Concurrent chemoradiotherapy**

  - `EBRT` to pelvis and para-aortic nodes
  - Weekly `cisplatin`
  - `Brachytherapy` boost

- **Hydronephrosis**: consider **nephrostomy** before starting therapy

### Stage IVA

> Bladder/rectum mucosa invasion

- **CCRT**

  - May require **palliative diversion** (e.g., colostomy, urostomy)

### Stage IVB

> Distant metastasis

- **Palliative chemotherapy**: cisplatin + paclitaxel ± bevacizumab
- **Palliative radiotherapy** for bleeding or pain control
- Supportive care (pain, anemia, infection, nutrition)

### Chemotherapy Agents Used

- `Cisplatin` (main radiosensitizer)
- `Paclitaxel + carboplatin` (metastatic disease)
- `Bevacizumab`: anti-VEGF, improves survival in metastatic disease

### Fertility-Sparing Options

- Only in **IA1–IB1** with small lesion (\<2 cm)
- **Radical trachelectomy** + lymphadenectomy
- Must exclude lymphovascular spread

### Complications of Radiotherapy

- Vaginal stenosis
- Ovarian failure
- Radiation cystitis/proctitis
- Bowel obstruction, fistula formation
- Lymphedema
